255 related articles for article (PubMed ID: 11248622)
1. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
[TBL] [Abstract][Full Text] [Related]
2. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
Shariat SF; Lamb DJ; Kattan MW; Nguyen C; Kim J; Beck J; Wheeler TM; Slawin KM
J Clin Oncol; 2002 Feb; 20(3):833-41. PubMed ID: 11821468
[TBL] [Abstract][Full Text] [Related]
3. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
8. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.
Ismail HA; Pollak M; Behlouli H; Tanguay S; Bégin LR; Aprikian AG
BJU Int; 2003 Nov; 92(7):699-702. PubMed ID: 14616449
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.
Bubley GJ; Balk SP; Regan MM; Duggan S; Morrissey ME; Dewolf WC; Salgami E; Mantzoros C
J Urol; 2002 Nov; 168(5):2249-52. PubMed ID: 12394769
[TBL] [Abstract][Full Text] [Related]
13. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
14. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
16. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
17. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
Lopez JB; Sahabudin RM; Chin LP
Int J Biol Markers; 2004; 19(2):164-7. PubMed ID: 15255551
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673
[TBL] [Abstract][Full Text] [Related]
19. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
20. Sequential changes in insulin-like growth factor I (IGF-I) and IGF-binding proteins in children with end-stage liver disease before and after successful orthotopic liver transplantation.
Holt RI; Jones JS; Stone NM; Baker AJ; Miell JP
J Clin Endocrinol Metab; 1996 Jan; 81(1):160-8. PubMed ID: 8550746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]